C5 and anemia (phenotype): In real-world patients receiving PEG as second-line therapy due to anemia experienced during C5 inhibition, one study revealed that 13 out of 48 patients experienced breakthrough hemolysis while receiving PEG or combination therapy with C5 inhibitors [39].